The Latest Breaking News from Wegovy

Novo Nordisk Increasingly Calls Wegovy Users Customers, Months After FDA Flagged a 'Live Lighter' Pill Ad Claim

STAT reports Novo now markets Wegovy to customers, months after the FDA called a Wegovy pill ad misleading. What cash-pay buyers should check first.

Medical Daily · Sep 30

Self-Pay Channels Make Up Half of Wegovy Business and 90% of Pill Demand as Families Weigh Cash Prices

Novo Nordisk says self-pay channels now make up half of its Wegovy business. Here is what cash prices cost families and which coverage options remain.

Medical Daily · Sep 23

Wegovy maker Novo Nordisk faces investor pressure to find growth beyond weight-loss drugs

Facing increased scrutiny, Novo Nordisk must clarify its future strategy outside of its leading weight-loss drug. Investors are advocating diversification into new therapy areas for sustainable growth. With Eli Lilly set to outshine its sales figures this year, analysts suggest a pivot towards developing zenagamtide instead of CagriSema. It is…

The Economic Times · Sep 21

Novo Nordisk A/S Q1 Earnings Call Highlights

Novo Nordisk A/S (NYSE:NVO) said its first quarter of 2026 was marked by rapid uptake of its newly launched Wegovy pill in the U.S., continued expansion of its obesity franchise and a series of pipeline and regulatory milestones, even as adjusted sales declined because of lower realized prices. Chi

MarketBeat · May 13

Early data links Wegovy to risk of 'eye stroke' — here's what to know

A rare form of vision loss has been linked to certain GLP-1s, but more so to Wegovy than to other weight-loss drugs in this class. Should you worry?

LiveScience · Apr 29

Wegovy Tragedy: Woman in Pain with 'Black Tongue' and Lost Organ After Weight Loss Jabs

Sarah-Jayne Crawford's weight-loss journey with Wegovy turned tragic, leading to severe health issues and organ removal. She now warns others about the potential risks of such treatments.

International Business Times UK · Apr 16

Novo Nordisk Just Announced Wegovy Subscriptions. Does That Make NVO Stock a Buy?

Wegovy subscriptions may create interest, but there is a major threat looming for Novo Nordisk.

Barchart · Apr 2

‘Major turning point’ as weight loss drugs to be prescribed to more NHS patients

Wegovy can now be prescribed for weight loss or to help reduce the risk of major cardiovascular events

The Independent UK · Mar 31

Ozempic Controversy Deepens as FDA Accuses Novo Nordisk of Failing to Report Patient Deaths, One Linked To Suicide

Novo Nordisk faces FDA scrutiny for failing to report Ozempic-linked deaths, highlighting systemic issues in safety reporting. Learn about the implications for patient safety and ongoing legal challenges.

International Business Times UK · Mar 16

Weight-loss jab could be made for $3 a month, study finds

Cheap semaglutide, the drug in Ozempic and Wegovy, could help millions with diabetes and obesity in 160 countries

The Guardian - UK · Mar 6